Amicus Pompe Disease Combo’s Approvability In Question As Key Trial Misses Mark
Company Touts ‘Totality Of Data’ As Supporting Approval
Executive Summary
The company hopes to score a nod from the US FDA based on a secondary endpoint that won approval for Sanofi’s Lumizyme.
You may also be interested in...
Amicus Spins Out Rare Disease Gene Therapy Pipeline, Raises $200m
While Amicus will transfer the gene therapy portfolio’s R&D risk to Caritas, it retains a financial interest in many of the spinout’s programs. Pompe candidate AT-GAA accepted for FDA review.
Orphan Drugs Dominate EU Fast-Track Request Decisions In July
The European Medicines Agency decided this month whether to grant fast-track review for planned marketing authorization applications for three potential new orphan treatments.
Parkinson’s Results Further Sweeten AbbVie’s Acquisition of Cerevel
Cerevel, which AbbVie is spending $8.7bn to acquire, unveiled topline results from the TEMPO-3 study of tavapadon, which an analyst said represents potentially a $1bn opportunity.